Athos, Cleveland Clinic to partner on IBD research

By The Science Advisory Board staff writers

August 25, 2021 -- Athos Therapeutics and the Cleveland Clinic have agreed to collaborate on inflammatory bowel disease (IBD) research. The agreement will advance the use of systems biology and computational science for precision medicine in inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Using a systems biology approach can enable clinicians to properly characterize the heterogeneity of the disease at the molecular level, the companies believe. From there, IBD patients can be classified into specific molecular subtypes, enabling the development of custom-made therapies.

Financial details of the collaboration were not disclosed.

If you like this content, please share it with a colleague!

Related Reading

SARS-CoV-2 PLpro enzyme may be an effective COVID-19 drug target
A coronavirus enzyme called papain-like protease (PLpro) that's capable of blocking host innate immune responses during infection may be an attractive...

Taysha establishes additional collaboration for minigene payloads
Taysha Gene Therapies has established a multiyear collaboration with a team of Yale University researchers. The goal is to advance next-generation minigene...

Taysha collaborates on minigene payloads for AAV gene therapy
Taysha Gene Therapies has established multiyear collaborations with the Cleveland Clinic and the University of Texas Southwestern Gene Therapy Program...

New drug target identified for common brain cancer
Research led by the Cleveland Clinic has identified a potential new therapy in the treatment of glioblastoma. An article published in Cancer Discovery...